EUVIMEDSkopri EUVIMED
FallberichtOpen access · CC BY-NC-ND 4.0

Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments

Vincent Fabry iD, Celso Rual, Chloé Bost, Blandine Acket, Julien Maquet, Pascal Cintas

European Journal of Neurology · 2025

DOI: 10.1111/ene.70285 ↗

At a glance

Fallbericht in European Journal of Neurology, 2025. Written by Vincent Fabry and 5 co-authors. Institution: Department of Neurology, Toulouse University Hospital, Toulouse Cedex 9, France. Major MEDLINE topics: Myasthenia Gravis, Autoantibodies, Nerve Tissue Proteins, Membrane Proteins. Cited 4 times so far (Crossref); 5 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Introduction

Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies against the acetylcholine receptor (AChR‐Ab). Morvan syndrome (MoS) is a rarer autoimmune disease with neuromyotonia, dysautonomia and encephalopathy, associated with antibodies targeting contactin‐associated protein‐like 2 (CASPR2) and may coexist with MG, particularly in patients with thymoma. Case Report A 57‐year‐old man with AChR‐Ab MG was treated with pyridostigmine and prednisone for one year and then presented with a severe exacerbation. The symptoms were not controlled despite intravenous immunoglobulins and plasmapheresis. Chest CT revealed a thymoma. Zilucoplan (a C5 complement inhibitor) was started, with rapid improvement. Efgartigimod (a neonatal Fc receptor (FcRn) antagonist) was added to stabilise residual symptoms prior to thymectomy. Three weeks after the third and final efgartigimod cycle, the patient had no symptoms of MG but began to develop profuse sweating, then generalised hypertonia, fasciculations, myoclonus and dysautonomia, consistent with MoS, which were confirmed by the presence of anti‐CASPR2 antibodies. Symptoms improved markedly after resumption of efgartigimod.

Conclusion

This case provides the first evidence of the efficacy of efgartigimod in the treatment of MoS and suggests that FcRn inhibition may be beneficial in IgG4‐mediated disorders beyond MG. It also highlights the importance of considering coexisting autoimmune conditions in thymoma, particularly when new symptoms occur under selective immune modulation. Finally, it emphasises the need to understand immunopathological mechanisms when choosing immunomodulatory treatment.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisAutoantibodiesNerve Tissue ProteinsMembrane ProteinsHumansMaleMiddle AgedThymomaThymus NeoplasmsPyridostigmine BromideSyndrome

Author keywords

anti‐CASPR2 autoantibodyautoimmunitycomplement C5myasthenia gravisneonatal Fc receptor

Substances

AutoantibodiesNerve Tissue ProteinsCNTNAP2 protein, humanMembrane ProteinsPyridostigmine Bromide

Authors and institutions

  • Department of Neurology, Toulouse University Hospital, Toulouse Cedex 9, France.
  • Department of Immunology, Federative Institute of Biology, Toulouse University Hospital, Toulouse Cedex 9, France.
  • Department of Internal Medicine, Toulouse University Hospital, Toulouse Cedex 9, France.

ORCID profiles: Vincent Fabry

Cite

APA

Fabry, V., Rual, C., Bost, C., Acket, B., Maquet, J., & Cintas, P. (2025). Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments. European Journal of Neurology. https://doi.org/10.1111/ene.70285

Vancouver

Fabry V, Rual C, Bost C, Acket B, Maquet J, Cintas P. Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments. European Journal of Neurology. 2025. doi:10.1111/ene.70285

BibTeX
@article{Fabry2025,
  author = {Fabry, Vincent and Rual, Celso and Bost, Chloé and Acket, Blandine and Maquet, Julien and Cintas, Pascal},
  title = {Unmasking Anti‐ CASPR2 Syndrome in a Patient Treated for Myasthenia Gravis in the Era of New Treatments},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70285}
}
Start for free →